-- 永明金融(Sun Life Financial,股票代码:SLF.TO)周三盘后公布,第一季度基本盈利增长,股息增加0.04美元。该公司还计划重启股票回购计划。 基本净利润小幅增长至10.5亿美元,合每股1.89美元,高于去年同期的10.45亿美元(合每股1.82美元)。Factset调查的分析师此前预期每股收益为1.89美元。永明金融表示,基本盈利增长主要得益于亚洲市场的强劲表现,反映了香港业务的增长;同时,加拿大市场也受益于管理资产规模(AUM)扩大带来的手续费收入增加。 基本股本回报率(ROE)从17.7%升至18.6%。 永明金融表示,管理资产规模(AUM)同比增长230亿美元,达到15780亿美元。 该公司将于6月30日向5月27日登记在册的股东派发每股0.96美元的更高股息。 Sun Life另行宣布,计划重启股票回购计划,自5月29日起回购至多1000万股,为期一年。该正常发行人回购计划还需获得加拿大金融机构监管办公室(OSFI)的批准。 Sun Life首席执行官Kevin Strain表示:“本季度,我们的保障业务实现了强劲增长,其中亚洲、加拿大和美国的健康与风险解决方案业务表现尤为突出。此外,我们还进一步扩大了资产管理平台的规模,投入超过24亿美元的资金收购了BGO和Crescent Capital,并宣布计划收购美国领先的多户住宅房地产投资管理公司和垂直整合型物业管理企业Bell Partners。” Sun Life Financial在纽约盘后交易中股价下跌0.09美元,至73.01美元。该股在多伦多证券交易所收盘下跌0.12美元,报99.53美元。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.